|
17 Nov 2020 |
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
|
|
17 Nov 2020 |
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
|
|
17 Nov 2020 |
Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study
|
|
17 Nov 2020 |
CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
|
|
17 Nov 2020 |
Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH
|
|
17 Nov 2020 |
Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx 99, an Experimental Treatment for Respiratory Viral Infection, Including COVID 19
|
|
17 Nov 2020 |
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
|
|
17 Nov 2020 |
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
|
|
17 Nov 2020 |
INOVIO announces initiation of Phase 2 segment of Phase 2/3 clinical trial for COVID-19 DNA vaccine candidate INO-4800
|
|
17 Nov 2020 |
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
|
|
17 Nov 2020 |
RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications
|
|
16 Nov 2020 |
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
|
|
16 Nov 2020 |
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
|
|
16 Nov 2020 |
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures
|
|
16 Nov 2020 |
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
|
|
16 Nov 2020 |
Samsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis® (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual
|
|
16 Nov 2020 |
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
|
|
16 Nov 2020 |
Calypso Biotech Announces Successful Dosing of First Phase 1 Cohort with Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 for the Treatment of Autoimmune Diseases
|
|
16 Nov 2020 |
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
|
|
16 Nov 2020 |
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
|
